The American Association of Clinical Endocrinologists/American College of Endocrinology consensus statement also recommends either a GLP-1RA or SGLT2i as a preferred treatment option (either as first-line or, more typically, second-line treatment after metformin) over alternative options such as a dipeptidyl peptidase-4 inhibitor, a thiazolidinedione (TZD), or a sulfonylurea (SU), for patients with T2D and ASCVD, stage 3 CKD, or heart failure with reduced ejection fraction [2]
[1] Patients should maintain realistic expectations, as skin changes may improve gradually over time as the body adjusts to its new weight
At QuickMD, we receive a lot of positive feedback from patients prescribed compounded tirzepatide
Evaluate Clinical Appropriateness The most immediate strategy for cost containment is rigorous clinical oversight to limit inappropriate use
They may be able to prescribe a covered GLP1 for a different indication, such as diabetes or cardiovascular disease, if you qualify